Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $100.78M by Medicaid between Jan 2018 and Dec 2024, across 574 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 10% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
NEW YORK, NY 10029
NEW YORK, NY 10029
33aNPI1013924372assigned 08/01/2006
33bProvider typeInternal Medicine Physician
28Total paid$100.78M
24GClaims2,276,971
24DCodes billed574
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#10 of 6,049
Median peer was paid$11K
This provider vs. median8,909×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,873 | $280K | |
| 2019 | 135,382 | $5.29M | |
| 2020 | 321,330 | $15.59M | |
| 2021 | 578,006 | $26.05M | |
| 2022 | 500,557 | $23.56M | |
| 2023 | 344,641 | $15.69M | |
| 2024incomplete | 317,182 | $14.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 121,596 | 107,300 | $10.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 46,506 | 42,127 | $8.55M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.5% | 77,344 | 68,254 | $6.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.1% | 32,739 | 29,652 | $6.17M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.4% | 67,592 | 58,316 | $4.48M |
| G0378 | Hospital observation service, per hour | 3.4% | 3,062 | 2,969 | $3.38M |
| S9123 | Nursing care, in the home; by registered nurse, per hour (use for general nursing care only, not to be used when cpt codes 99500-99602 can be used) | 3.0% | 9,185 | 8,921 | $3.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 11,654 | 10,826 | $2.46M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.3% | 19,074 | 10,997 | $2.35M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 2.1% | 51,105 | 7,649 | $2.13M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.9% | 28,064 | 25,076 | $1.92M |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 150,167 | 86,472 | $1.88M |
562 more codes
| 99203 | Doctor's office visit, new patient (routine) | 1.8% | 15,725 | $1.85M |
| 99204 | Doctor's office visit, new patient (more involved) | 1.8% | 12,088 | $1.84M |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1.3% | 21,015 | $1.28M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 7,683 | $1.20M |
| 99285 | Emergency room visit (most serious) | 1.2% | 5,460 | $1.19M |
| J1644 | Injection, heparin sodium, per 1000 units | 1.1% | 22,589 | $1.15M |
| 90834 | Psychotherapy session, about 45 minutes | 1.1% | 7,414 | $1.12M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 64,098 | $1.09M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 26,133 | $1.09M |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,111 | $994K |
| 99205 | Prolong outpt/office vis | <1% | 4,642 | $837K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 15,912 | $832K |
| 81408 | <1% | 532 | $742K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,631 | $722K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,138 | $697K |
| S9131 | Physical therapy; in the home, per diem | <1% | 1,861 | $677K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,043 | $642K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 5,226 | $638K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 886 | $634K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28,953 | $597K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,495 | $580K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,475 | $569K |
| 99442 | <1% | 9,886 | $568K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 16,615 | $533K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,064 | $529K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 32,811 | $527K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15,963 | $475K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 699 | $428K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 877 | $417K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,836 | $402K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 783 | $398K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,014 | $392K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,296 | $380K |
| 99051 | <1% | 10,501 | $367K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13,445 | $361K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,253 | $350K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,688 | $349K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 43,555 | $335K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,037 | $334K |
| 80061 | Lipid panel | <1% | 32,551 | $330K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,246 | $329K |
| S9122 | Home health aide or certified nurse assistant, providing care in the home; per hour | <1% | 302 | $317K |
| 99443 | <1% | 4,299 | $314K | |
| 86480 | <1% | 5,040 | $307K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,541 | $303K |
| 85027 | <1% | 77,722 | $303K | |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 1,873 | $299K |
| 82948 | <1% | 25,672 | $291K | |
| 80053 | Comprehensive metabolic panel | <1% | 23,749 | $270K |
| 90461 | <1% | 11,597 | $270K | |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 1,818 | $250K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12,792 | $242K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32,806 | $239K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 33,486 | $231K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,710 | $229K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,368 | $218K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,711 | $212K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 2,831 | $212K |
| J0606 | Injection, etelcalcetide, 0.1 mg | <1% | 3,293 | $211K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,094 | $208K |
| 99201 | <1% | 2,844 | $203K | |
| 97161 | <1% | 2,373 | $203K | |
| 86703 | <1% | 15,136 | $201K | |
| H0040 | Assertive community treatment program, per diem | <1% | 126 | $196K |
| 76770 | <1% | 1,431 | $194K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,700 | $193K |
| 80076 | <1% | 30,961 | $189K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,034 | $188K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,911 | $187K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,172 | $180K |
| 76641 | <1% | 1,568 | $175K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 9,991 | $168K |
| S9127 | Social work visit, in the home, per diem | <1% | 1,317 | $165K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,633 | $162K |
| 99441 | <1% | 4,259 | $156K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,980 | $154K |
| 81422 | <1% | 234 | $154K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,564 | $153K |
| 90750 | <1% | 2,086 | $153K | |
| 0002A | <1% | 5,914 | $152K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,499 | $150K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,719 | $148K |
| 0001A | <1% | 6,047 | $144K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 2,276 | $143K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 554 | $141K |
| 97802 | <1% | 5,192 | $140K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 5,511 | $138K |
| 93970 | <1% | 692 | $136K | |
| 90677 | <1% | 1,225 | $135K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 800 | $135K |
| 90715 | <1% | 5,362 | $134K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,632 | $123K |
| 87536 | <1% | 1,279 | $121K | |
| 90651 | <1% | 2,409 | $120K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,579 | $118K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 954 | $118K |
| 76801 | <1% | 930 | $116K | |
| 81161 | <1% | 544 | $115K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 9,132 | $110K |
| 71250 | <1% | 588 | $109K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 539 | $108K |
| 81329 | <1% | 854 | $107K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,570 | $107K |
| 81405 | <1% | 511 | $106K | |
| 90686 | <1% | 15,672 | $102K | |
| 88312 | <1% | 1,079 | $101K | |
| 99381 | <1% | 2,778 | $100K | |
| 86850 | <1% | 6,624 | $99K | |
| 0004A | <1% | 2,631 | $98K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,985 | $97K |
| 83655 | <1% | 8,856 | $96K | |
| 86803 | <1% | 8,764 | $95K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,344 | $95K |
| 92250 | <1% | 2,390 | $94K | |
| 86780 | <1% | 9,259 | $94K | |
| 86003 | <1% | 2,146 | $93K | |
| 96040 | <1% | 1,150 | $90K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,640 | $89K |
| 86769 | <1% | 2,947 | $82K | |
| 76536 | <1% | 744 | $78K | |
| 73630 | <1% | 3,617 | $77K | |
| 86360 | <1% | 1,547 | $76K | |
| 97010 | <1% | 10,066 | $75K | |
| 90734 | <1% | 1,576 | $75K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,585 | $74K |
| 80358 | <1% | 6,504 | $73K | |
| 90746 | <1% | 1,273 | $70K | |
| 81361 | <1% | 548 | $67K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,884 | $66K |
| 70486 | <1% | 520 | $66K | |
| 92015 | Determination of refractive state | <1% | 2,789 | $66K |
| 87340 | <1% | 8,689 | $65K | |
| 71271 | <1% | 255 | $61K | |
| 86359 | <1% | 1,545 | $59K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 592 | $58K |
| 86901 | <1% | 6,735 | $58K | |
| 90697 | <1% | 1,147 | $58K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,626 | $56K |
| 84703 | <1% | 16,729 | $54K | |
| 11900 | <1% | 446 | $51K | |
| 81401 | <1% | 525 | $51K | |
| 73610 | <1% | 2,264 | $51K | |
| 81507 | <1% | 77 | $50K | |
| 81243 | <1% | 1,026 | $49K | |
| 94729 | <1% | 915 | $49K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,939 | $48K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 661 | $48K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 7,504 | $48K |
| 99402 | <1% | 722 | $47K | |
| 86706 | <1% | 5,726 | $46K | |
| 90716 | <1% | 1,979 | $46K | |
| 94664 | <1% | 2,276 | $44K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,555 | $44K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,888 | $44K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,389 | $43K |
| 86900 | <1% | 6,714 | $43K | |
| 90723 | <1% | 1,974 | $43K | |
| 92570 | <1% | 1,041 | $42K | |
| 87800 | <1% | 1,273 | $42K | |
| 0072A | <1% | 1,009 | $40K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 2,376 | $40K |
| 81257 | <1% | 557 | $40K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 959 | $40K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,440 | $40K |
| 96127 | <1% | 18,206 | $39K | |
| 76818 | <1% | 324 | $38K | |
| 73130 | <1% | 1,997 | $38K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,022 | $38K |
| 97165 | <1% | 434 | $38K | |
| 90732 | <1% | 404 | $38K | |
| 81001 | <1% | 19,963 | $37K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 94 | $37K |
| 90707 | <1% | 2,036 | $37K | |
| 92551 | <1% | 11,130 | $37K | |
| 86762 | <1% | 2,821 | $37K | |
| 0071A | <1% | 1,078 | $36K | |
| 88142 | <1% | 1,617 | $36K | |
| 73560 | <1% | 1,342 | $36K | |
| 97803 | <1% | 522 | $34K | |
| 99382 | <1% | 643 | $34K | |
| 0124A | <1% | 773 | $33K | |
| 17110 | <1% | 172 | $33K | |
| 82728 | <1% | 3,268 | $32K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 19 | $32K |
| 73030 | <1% | 1,565 | $32K | |
| 82805 | <1% | 4,051 | $32K | |
| 73564 | <1% | 1,167 | $32K | |
| 72100 | <1% | 1,069 | $32K | |
| 86765 | <1% | 2,672 | $31K | |
| 69210 | <1% | 185 | $31K | |
| 80361 | <1% | 1,622 | $31K | |
| 90680 | <1% | 1,190 | $31K | |
| 84146 | <1% | 1,598 | $30K | |
| 90480 | <1% | 845 | $29K | |
| 92557 | <1% | 772 | $29K | |
| 87522 | Neg quan hep c or qual rna | <1% | 749 | $29K |
| 86787 | <1% | 2,650 | $28K | |
| 94010 | <1% | 667 | $28K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 133 | $28K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 307 | $27K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 925 | $27K |
| 84439 | <1% | 3,640 | $27K | |
| 82607 | <1% | 2,905 | $27K | |
| 92134 | <1% | 709 | $27K | |
| 83020 | <1% | 2,081 | $26K | |
| 87486 | <1% | 1,767 | $26K | |
| 82785 | <1% | 1,752 | $26K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 192 | $25K |
| 97116 | <1% | 1,152 | $25K | |
| 99384 | <1% | 391 | $24K | |
| 86735 | <1% | 2,268 | $24K | |
| 81255 | <1% | 538 | $23K | |
| 81400 | <1% | 525 | $23K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 4,252 | $23K |
| 83880 | <1% | 1,959 | $23K | |
| 86318 | <1% | 297 | $23K | |
| 83001 | <1% | 1,244 | $23K | |
| 92579 | <1% | 420 | $22K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 739 | $22K |
| 90670 | <1% | 4,063 | $22K | |
| 81251 | <1% | 538 | $22K | |
| 81200 | <1% | 538 | $22K | |
| 82105 | <1% | 1,592 | $21K | |
| 84153 | <1% | 1,442 | $21K | |
| H1005 | Prenatal care, at-risk enhanced service package (includes h1001-h1004) | <1% | 353 | $21K |
| 87581 | <1% | 1,768 | $21K | |
| 90620 | <1% | 847 | $21K | |
| 86704 | <1% | 2,220 | $21K | |
| 73110 | <1% | 1,053 | $21K | |
| 91320 | <1% | 418 | $20K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 88 | $20K |
| 73502 | <1% | 721 | $20K | |
| 90698 | <1% | 1,124 | $20K | |
| 82951 | <1% | 1,795 | $19K | |
| H0049 | Alcohol and/or drug screening | <1% | 1,401 | $19K |
| 99385 | <1% | 350 | $19K | |
| 90633 | <1% | 2,072 | $19K | |
| 84702 | <1% | 2,983 | $19K | |
| 83002 | <1% | 1,028 | $19K | |
| 87535 | <1% | 534 | $19K | |
| 81260 | <1% | 538 | $18K | |
| 99383 | <1% | 284 | $18K | |
| 92567 | <1% | 788 | $18K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,784 | $17K |
| 10060 | <1% | 125 | $17K | |
| 85610 | <1% | 7,687 | $17K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 483 | $16K |
| 83550 | <1% | 2,957 | $16K | |
| 90656 | <1% | 1,307 | $16K | |
| 92083 | <1% | 339 | $16K | |
| 92133 | <1% | 489 | $16K | |
| 88304 | <1% | 470 | $15K | |
| 81025 | <1% | 3,741 | $15K | |
| 96161 | <1% | 3,824 | $14K | |
| 94726 | <1% | 183 | $14K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,376 | $13K |
| 83540 | <1% | 3,028 | $13K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $13K |
| 83970 | <1% | 477 | $13K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 99 | $13K |
| 84484 | <1% | 8,556 | $13K | |
| 76870 | <1% | 176 | $12K | |
| 82043 | <1% | 2,987 | $12K | |
| 92558 | <1% | 653 | $12K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,741 | $12K |
| 93017 | <1% | 246 | $12K | |
| 87081 | <1% | 2,490 | $12K | |
| 83525 | <1% | 1,035 | $12K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $11K |
| 84402 | <1% | 478 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 238 | $11K |
| 96367 | <1% | 524 | $11K | |
| 85730 | <1% | 5,276 | $11K | |
| 90648 | <1% | 1,290 | $11K | |
| 86708 | <1% | 1,033 | $11K | |
| 84403 | <1% | 411 | $11K | |
| 83735 | <1% | 7,916 | $10K | |
| 90674 | <1% | 462 | $10K | |
| 90647 | <1% | 1,165 | $10K | |
| 83516 | <1% | 863 | $10K | |
| S9129 | Occupational therapy, in the home, per diem | <1% | 54 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,924 | $10K |
| 82977 | <1% | 2,599 | $10K | |
| 80047 | <1% | 1,164 | $10K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 429 | $9K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $9K |
| 87186 | <1% | 1,790 | $9K | |
| 77080 | <1% | 294 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,090 | $9K |
| 87338 | <1% | 852 | $9K | |
| 88141 | <1% | 459 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,584 | $9K |
| 80320 | <1% | 3,448 | $9K | |
| 94060 | <1% | 88 | $9K | |
| 82746 | <1% | 977 | $9K | |
| 12001 | <1% | 42 | $8K | |
| 0081A | <1% | 181 | $8K | |
| 86038 | <1% | 844 | $8K | |
| 82274 | <1% | 690 | $8K | |
| 82310 | <1% | 220 | $8K | |
| J0515 | Injection, benztropine mesylate, per 1 mg | <1% | 394 | $8K |
| 0154A | <1% | 184 | $8K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,651 | $8K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,275 | $7K |
| 82652 | <1% | 228 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,944 | $7K |
| 90696 | <1% | 534 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 53 | $7K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,121 | $7K |
| 99401 | <1% | 275 | $7K | |
| 36593 | <1% | 13 | $7K | |
| 90700 | <1% | 526 | $6K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 109 | $6K |
| 73590 | <1% | 468 | $6K | |
| 88300 | <1% | 540 | $6K | |
| 83690 | <1% | 6,164 | $6K | |
| 29125 | <1% | 41 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 419 | $6K |
| 97162 | <1% | 54 | $5K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,462 | $5K |
| 82784 | <1% | 510 | $5K | |
| 86140 | <1% | 1,657 | $5K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 639 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,360 | $5K |
| 80348 | <1% | 340 | $5K | |
| 95812 | <1% | 12 | $5K | |
| 76000 | <1% | 73 | $5K | |
| 82248 | <1% | 1,252 | $5K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,093 | $5K |
| 99397 | <1% | 202 | $5K | |
| 31575 | <1% | 14 | $5K | |
| 73565 | <1% | 128 | $5K | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 144 | $5K |
| 82570 | <1% | 1,262 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 52 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,562 | $4K |
| 0082A | <1% | 107 | $4K | |
| 82550 | <1% | 3,313 | $4K | |
| 85651 | <1% | 1,682 | $4K | |
| D0274 | Bitewings - four radiographic images | <1% | 743 | $4K |
| 83718 | <1% | 519 | $4K | |
| 86376 | <1% | 293 | $4K | |
| 0074A | <1% | 98 | $4K | |
| D1110 | Prophylaxis - adult | <1% | 320 | $4K |
| 90681 | <1% | 1,237 | $4K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,297 | $4K |
| 99409 | <1% | 291 | $4K | |
| 74178 | <1% | 12 | $4K | |
| 73562 | <1% | 280 | $4K | |
| 92550 | <1% | 117 | $4K | |
| 76813 | <1% | 30 | $3K | |
| 82670 | <1% | 121 | $3K | |
| 84156 | <1% | 1,154 | $3K | |
| D0330 | Panoramic radiographic image | <1% | 318 | $3K |
| S9470 | Nutritional counseling, dietitian visit | <1% | 25 | $3K |
| 99152 | <1% | 238 | $3K | |
| 93308 | <1% | 46 | $3K | |
| 99386 | <1% | 41 | $3K | |
| 73140 | <1% | 137 | $3K | |
| 92587 | <1% | 126 | $3K | |
| 96376 | <1% | 1,342 | $3K | |
| 82677 | <1% | 115 | $3K | |
| 83527 | <1% | 191 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,679 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,118 | $3K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 16 | $3K |
| 73090 | <1% | 194 | $3K | |
| 85045 | <1% | 879 | $2K | |
| 92202 | <1% | 108 | $2K | |
| 82465 | <1% | 573 | $2K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 52 | $2K |
| 84100 | <1% | 1,228 | $2K | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 70 | $2K |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 13 | $2K |
| 90662 | <1% | 251 | $2K | |
| 82803 | <1% | 727 | $2K | |
| 87631 | <1% | 151 | $2K | |
| 82247 | <1% | 556 | $2K | |
| 90744 | <1% | 265 | $2K | |
| 95117 | <1% | 181 | $2K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 308 | $2K |
| 96380 | <1% | 228 | $2K | |
| 70498 | <1% | 15 | $2K | |
| 99241 | <1% | 14 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 67 | $2K |
| 86592 | <1% | 749 | $2K | |
| 98960 | <1% | 82 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 33 | $2K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 33 | $2K |
| 76857 | <1% | 53 | $2K | |
| 94760 | <1% | 783 | $2K | |
| 83605 | <1% | 1,464 | $2K | |
| 80354 | <1% | 4,152 | $2K | |
| D1206 | Topical application of fluoride varnish | <1% | 578 | $2K |
| S3645 | Hiv-1 antibody testing of oral mucosal transudate | <1% | 30 | $2K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 177 | $2K |
| 88160 | <1% | 80 | $2K | |
| 87521 | Neg quan hep c or qual rna | <1% | 70 | $2K |
| D0120 | Dental checkup, returning patient | <1% | 339 | $2K |
| 84704 | <1% | 115 | $2K | |
| 81003 | <1% | 824 | $2K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 41 | $2K |
| 73070 | <1% | 106 | $2K | |
| 86336 | <1% | 115 | $2K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 26 | $2K |
| 85379 | <1% | 966 | $2K | |
| 73521 | <1% | 102 | $2K | |
| 80165 | <1% | 196 | $2K | |
| 87177 | <1% | 144 | $2K | |
| 86696 | <1% | 87 | $1K | |
| 93923 | <1% | 12 | $1K | |
| 90653 | <1% | 110 | $1K | |
| 99188 | <1% | 189 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 36 | $1K |
| 90694 | <1% | 108 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,871 | $1K |
| 86255 | <1% | 99 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,442 | $1K |
| 82150 | <1% | 320 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 925 | $1K |
| 80346 | <1% | 126 | $1K | |
| 0012A | <1% | 59 | $1K | |
| 77072 | <1% | 41 | $1K | |
| 0083A | <1% | 25 | $1K | |
| 86580 | <1% | 1,219 | $1K | |
| 59025 | Fetal non-stress test | <1% | 12 | $1K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 59 | $1K |
| 99493 | <1% | 32 | $1K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 411 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,631 | $1K |
| 87517 | <1% | 24 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,084 | $868.80 |
| 83519 | <1% | 51 | $864.16 | |
| 86695 | <1% | 66 | $845.47 | |
| 0011A | <1% | 59 | $814.46 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,242 | $810.49 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 531 | $803.18 |
| 93325 | <1% | 34 | $798.37 | |
| 86800 | <1% | 52 | $788.88 | |
| 99173 | <1% | 5,381 | $783.74 | |
| 92227 | <1% | 30 | $758.45 | |
| 84305 | <1% | 41 | $757.94 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 203 | $736.80 |
| 87070 | <1% | 343 | $735.77 | |
| 86430 | <1% | 152 | $733.33 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,281 | $731.14 |
| 82010 | <1% | 580 | $698.83 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 79 | $683.17 |
| 90678 | <1% | 77 | $676.79 | |
| 83615 | <1% | 188 | $653.23 | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 14 | $640.57 |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 83 | $619.50 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 69 | $598.10 |
| 91318 | <1% | 31 | $595.20 | |
| 91319 | <1% | 105 | $585.20 | |
| 15853 | <1% | 13 | $583.28 | |
| 93971 | <1% | 14 | $571.89 | |
| 84154 | <1% | 31 | $542.07 | |
| 82962 | <1% | 736 | $519.89 | |
| 87040 | <1% | 276 | $511.51 | |
| 88271 | <1% | 19 | $498.91 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $484.86 |
| 71101 | <1% | 27 | $473.34 | |
| 74018 | <1% | 29 | $459.76 | |
| 86705 | <1% | 45 | $456.32 | |
| 83010 | <1% | 44 | $454.63 | |
| J1815 | Injection, insulin, per 5 units | <1% | 678 | $440.83 |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 29 | $430.11 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 772 | $415.66 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 239 | $392.02 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,180 | $385.10 |
| 84481 | <1% | 25 | $384.36 | |
| 86709 | <1% | 44 | $376.85 | |
| 99407 | <1% | 12 | $375.00 | |
| 85018 | <1% | 157 | $369.95 | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 12 | $344.16 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 4,053 | $332.64 |
| D0210 | Intraoral - complete series of radiographic images | <1% | 97 | $332.14 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 61 | $330.72 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,232 | $329.60 |
| 87590 | <1% | 652 | $322.78 | |
| D9310 | <1% | 15 | $312.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 450 | $298.91 |
| 3074F | <1% | 33,791 | $290.02 | |
| 82533 | <1% | 14 | $289.54 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 214 | $284.75 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,240 | $266.15 |
| 0073A | <1% | 13 | $264.54 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 880 | $264.13 |
| 90381 | <1% | 33 | $252.22 | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 24 | $242.93 |
| 85014 | <1% | 677 | $234.73 | |
| 96368 | <1% | 13 | $231.27 | |
| 85660 | <1% | 48 | $228.05 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 3,094 | $219.28 |
| 82952 | <1% | 52 | $212.35 | |
| 83883 | <1% | 15 | $211.36 | |
| 99406 | <1% | 73 | $211.06 | |
| 90714 | <1% | 54 | $208.79 | |
| 3078F | <1% | 38,067 | $195.83 | |
| D9430 | <1% | 32 | $193.60 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,141 | $186.12 |
| D1120 | Dental cleaning, child | <1% | 48 | $175.00 |
| 73080 | <1% | 29 | $167.78 | |
| 3079F | <1% | 7,907 | $164.46 | |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | <1% | 29 | $156.05 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 132 | $155.55 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 75 | $155.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 338 | $150.33 |
| 86593 | <1% | 52 | $129.31 | |
| 87077 | <1% | 258 | $128.41 | |
| 81000 | <1% | 662 | $126.53 | |
| 90474 | <1% | 12 | $125.57 | |
| 86225 | <1% | 12 | $122.75 | |
| 73060 | <1% | 12 | $114.80 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 51 | $106.94 |
| 82390 | <1% | 12 | $104.31 | |
| D0191 | <1% | 162 | $97.99 | |
| 88399 | <1% | 150 | $89.93 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 219 | $82.87 |
| G0008 | Administration of influenza virus vaccine | <1% | 259 | $75.30 |
| 90688 | <1% | 13 | $73.18 | |
| 96160 | <1% | 18 | $54.48 | |
| 82553 | <1% | 13 | $45.44 | |
| 84550 | <1% | 13 | $42.48 | |
| 93321 | <1% | 17 | $37.16 | |
| 87490 | <1% | 649 | $35.61 | |
| 81002 | <1% | 29 | $34.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 52 | $33.09 |
| 84155 | <1% | 13 | $32.98 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 13 | $29.67 |
| 90611 | <1% | 37 | $26.54 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 16 | $15.90 |
| D0272 | Bitewings - two radiographic images | <1% | 12 | $7.50 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 14 | $0.59 |
| 3077F | <1% | 5,578 | $0.17 | |
| 1159F | 0% | 6,643 | $0.00 | |
| 48510 | 0% | 149 | $0.00 | |
| 1160F | 0% | 4,381 | $0.00 | |
| 90685 | 0% | 1,162 | $0.00 | |
| 99080 | 0% | 1,453 | $0.00 | |
| 0502F | 0% | 105 | $0.00 | |
| 3016F | 0% | 580 | $0.00 | |
| 99499 | 0% | 4,163 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 52 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 33 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 99 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 16 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 112 | $0.00 |
| 3075F | 0% | 9,612 | $0.00 | |
| 4293F | 0% | 635 | $0.00 | |
| 1220F | 0% | 928 | $0.00 | |
| G0436 | Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes | 0% | 580 | $0.00 |
| 3080F | 0% | 2,200 | $0.00 | |
| 99429 | 0% | 180 | $0.00 | |
| 1126F | 0% | 119 | $0.00 | |
| 3008F | 0% | 264 | $0.00 | |
| 80050 | General health panel | 0% | 14 | $0.00 |
| 88720 | 0% | 14 | $0.00 | |
| 3044F | 0% | 346 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.